AGC Biologics


Prioritizing R&D Initiatives to Support Cell Line Development (January 2024)

Robust, scalable manufacturing of novel therapeutics requires partnering with a CDMO equipped to adapt to changes in the market and knowledgeable on the latest technologies used to support cell line development.

New Market Opportunities for Pathogen-Targeted mAbs

This research outlines recent changes in the monoclonal antibody market, the great potential for pathogen-focused mAb treatments and important industry factors impacting how to antibody products can navigate through clinical stages.